In addition, the positive research progress on small molecule inhibitors acting on BRDs has made it possible to target these BRD-containing proteins, such as ATAD2, for the diagnosis and treatment of HCC [23, 24]. The gene discussed is ATAD2; the disease is hepatocellular carcinoma.